Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis.

Literature DB >> 27788692

Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis.

Pei-Hsin Kuo¹, Sheng-Han Kuo², Raymond Y Lo¹.

Abstract

Entities: Chemical Disease Gene Species

Keywords: Superficial siderosis; ataxia; deferiprone

Mesh：

Substances：

Year: 2016 PMID： 27788692 PMCID： PMC6089358 DOI： 10.1017/cjn.2016.329

Source DB: PubMed Journal: Can J Neurol Sci ISSN： 0317-1671 Impact factor: 2.104

× No keyword cloud information.

5 in total

1. Update on a patient with superficial siderosis on deferiprone.

Authors: M Levy; R H Llinas
Journal: AJNR Am J Neuroradiol Date: 2012-05-10 Impact factor: 3.825

2. Pilot safety trial of deferiprone in 10 subjects with superficial siderosis.

Authors: Michael Levy; Rafael Llinas
Journal: Stroke Date: 2011-10-27 Impact factor: 7.914

3. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

Authors: Massimo Pandolfo; Javier Arpa; Martin B Delatycki; Kim Hanh Le Quan Sang; Caterina Mariotti; Arnold Munnich; Irene Sanz-Gallego; Geneieve Tai; Mark A Tarnopolsky; Franco Taroni; Michael Spino; Fernando Tricta
Journal: Ann Neurol Date: 2014-08-30 Impact factor: 10.422

4. Scale for the assessment and rating of ataxia: development of a new clinical scale.

Authors: T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu
Journal: Neurology Date: 2006-06-13 Impact factor: 9.910

5. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.

Authors: Giovanni Cossu; Giovanni Abbruzzese; Gildo Matta; Daniela Murgia; Maurizio Melis; Valeria Ricchi; Renzo Galanello; Susanna Barella; Raffaella Origa; Manuela Balocco; Elisa Pelosin; Roberta Marchese; Uberto Ruffinengo; Gian Luca Forni
Journal: Parkinsonism Relat Disord Date: 2014-03-12 Impact factor: 4.891

5 in total

Review 1. Ataxia.

Authors: Sheng-Han Kuo
Journal: Continuum (Minneap Minn) Date: 2019-08

Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis.

1. Update on a patient with superficial siderosis on deferiprone.

2. Pilot safety trial of deferiprone in 10 subjects with superficial siderosis.

3. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

4. Scale for the assessment and rating of ataxia: development of a new clinical scale.

5. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.

Review 1. Ataxia.

2. Two-year observational study of deferiprone in superficial siderosis.

Review 3. Recent Advances in the Treatment of Cerebellar Disorders.

4. Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review.

5. Focused Neuro-Otological Review of Superficial Siderosis of the Central Nervous System.